OrbiMed’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-26,100
| Closed | -$2.15M | – | 121 |
|
|
2024
Q2 | $2.15M | Sell |
26,100
-1,252,400
| -98% | -$104M | 0.04% | 103 |
|
|
2024
Q1 | $112M | Sell |
1,278,500
-292,910
| -19% | -$26.2M | 2.05% | 11 |
|
|
2023
Q4 | $152M | Sell |
1,571,410
-43,800
| -3% | -$3.87M | 3.03% | 7 |
|
|
2023
Q3 | $143M | Hold |
1,615,210
| – | – | 3.04% | 6 |
|
|
2023
Q2 | $140M | Hold |
1,615,210
| – | – | 2.54% | 9 |
|
|
2023
Q1 | $157M | Hold |
1,615,210
| – | – | 3.08% | 7 |
|
|
2022
Q4 | $167M | Sell |
1,615,210
-102,100
| -6% | -$9.58M | 3.2% | 6 |
|
|
2022
Q3 | $146K | Buy |
1,717,310
+17,600
| +1% | +$1.57M | 2.7% | 6 |
|
|
2022
Q2 | $141K | Buy |
1,699,710
+52,680
| +3% | +$4.19M | 2.55% | 10 |
|
|
2022
Q1 | $127M | Buy |
1,647,030
+786,150
| +91% | +$65.8M | 2.06% | 15 |
|
|
2021
Q4 | $76.1M | Buy |
860,880
+749,980
| +676% | +$61.9M | 0.98% | 35 |
|
|
2021
Q3 | $8.57M | Buy |
+110,900
| New | +$8.75M | 0.09% | 135 |
|
|
2020
Q2 | – | Sell |
-540,500
| Closed | -$45.7M | – | 141 |
|
|
2020
Q1 | $45.7M | Buy |
540,500
+505,800
| +1,458% | +$43.6M | 0.77% | 42 |
|
|
2019
Q4 | $2.93M | Buy |
+34,700
| New | +$2.62M | 0.04% | 113 |
|
|
2019
Q3 | – | Sell |
-75,000
| Closed | -$6.42M | – | 122 |
|
|
2019
Q2 | $6.42M | Sell |
75,000
-1,500
| -2% | -$128K | 0.1% | 102 |
|
|
2019
Q1 | $6.79M | Hold |
76,500
| – | – | 0.11% | 99 |
|
|
2018
Q4 | $6.51M | Hold |
76,500
| – | – | 0.12% | 96 |
|
|
2018
Q3 | $7.42M | Hold |
76,500
| – | – | 0.09% | 120 |
|
|
2018
Q2 | $7.21M | Sell |
76,500
-69,000
| -47% | -$6.04M | 0.09% | 120 |
|
|
2018
Q1 | $11.8M | Buy |
145,500
+44,900
| +45% | +$3.85M | 0.15% | 101 |
|
|
2017
Q4 | $8.97M | Sell |
100,600
-643,300
| -86% | -$55.9M | 0.11% | 105 |
|
|
2017
Q3 | $69.2M | Sell |
743,900
-238,700
| -24% | -$21.1M | 0.66% | 45 |
|
|
2017
Q2 | $89.2M | Sell |
982,600
-291,500
| -23% | -$26.5M | 0.94% | 35 |
|
|
2017
Q1 | $112M | Hold |
1,274,100
| – | – | 1.27% | 26 |
|
|
2016
Q4 | $106M | Buy |
1,274,100
+122,200
| +11% | +$10.5M | 1.34% | 26 |
|
|
2016
Q3 | $107M | Sell |
1,151,900
-366,600
| -24% | -$34.5M | 1.21% | 27 |
|
|
2016
Q2 | $118M | Buy |
1,518,500
+495,300
| +48% | +$42.1M | 1.23% | 28 |
|
|
2016
Q1 | $84.4M | Buy |
1,023,200
+874,200
| +587% | +$71.1M | 0.89% | 35 |
|
|
2015
Q4 | $15.6M | Sell |
149,000
-39,000
| -21% | -$4.07M | 0.14% | 77 |
|
|
2015
Q3 | $19.8M | Hold |
188,000
| – | – | 0.2% | 75 |
|
|
2015
Q2 | $25.7M | Buy |
+188,000
| New | +$23.3M | 0.21% | 76 |
|
|
2014
Q3 | – | Sell |
-1,435,400
| Closed | -$89.3M | – | 133 |
|
|
2014
Q2 | $89.3M | Sell |
1,435,400
-57,600
| -4% | -$3.48M | 1.05% | 35 |
|
|
2014
Q1 | $102M | Buy |
1,493,000
+78,900
| +6% | +$5.81M | 1.25% | 27 |
|
|
2013
Q4 | $99.5M | Sell |
1,414,100
-167,600
| -11% | -$11.4M | 1.46% | 25 |
|
|
2013
Q3 | $114M | Buy |
1,581,700
+240,500
| +18% | +$16M | 2.04% | 17 |
|
|
2013
Q2 | $74.8M | Buy |
+1,341,200
| New | +$83.6M | 1.58% | 24 |
|
Other funds holding BMRN
EIM
OrbiMed's BMRN Position: Q3 2024 in Review
OrbiMed sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 26,100 shares — an estimated $2.15M sold.
OrbiMed first reported a position in BMRN in Q2 2013 and held it in 36 quarters. The position peaked at $167M in Q4 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.
- OrbiMed reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
- OrbiMed sold 26,100 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $2.15M.
- OrbiMed first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 36 quarters.
- OrbiMed's BioMarin Pharmaceuticals position peaked at $167M in Q4 2022.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.
Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.